Want to see JP:4886 full AI Analyst Report?
4886 Stock Chart & Stats
¥2038.00
-¥23.00(-1.13%)
At close: 4:00 PM EST
¥2038.00
-¥23.00(-1.13%)
Day’s Range― - ―
52-Week Range¥1,920.00 - ¥3,045.00
Previous CloseN/A
Volume48.10K
Average Volume (3M)49.10K
Market Cap
¥60.12B
Enterprise Value¥58.68B
Total Cash (Recent Filing)¥11.02B
Total Debt (Recent Filing)¥11.43B
Price to Earnings (P/E)11.7
Beta0.60
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)191.08
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)0.96
Price to Sales (P/S)0.94
P/FCF Ratio17.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetA markedly lower debt burden alongside materially higher equity improves financial flexibility and reduces default and refinancing risk. This enduring capital structure supports sustained R&D investment, manufacturing capacity and strategic optionality (licensing, M&A or share returns) over the medium term.
Multi-year Revenue GrowthConsistent top-line expansion demonstrates durable demand for the company’s branded pharmaceuticals and successful commercialization. Steady revenue provides a reliable base to fund pipeline development, absorb pricing pressure, and sustain manufacturing scale, supporting resilient operations over coming quarters.
Healthy Recurring ProfitabilitySustained gross-profit strength indicates persistent margin on core products and structural ability to generate operating profits. This margin durability underpins reinvestment capacity into R&D and commercialization, and provides a buffer against reimbursement shifts or cost inflation over the medium term.
Bears Say
Volatile Cash GenerationIrregular operating and free cash flow reduces predictability for funding R&D, capital expenditures and dividends without tapping reserves. Working-capital swings or lumpy investment timing can constrain strategic execution and increase reliance on retained equity or external funding in stress periods.
Earnings And ROE VariabilityFluctuating profitability and ROE signal uneven profit efficiency and sensitivity to product cycles or one-off items. That variability complicates forecasting, weakens return predictability for investors, and may constrain management’s ability to commit to steady capital returns or long-term projects.
Concentration In Domestic, Reimbursement-driven MarketHeavy reliance on Japan’s reimbursement framework exposes revenues and margins to regulatory pricing revisions and public-payor decisions. Limited geographic or commercial diversification raises structural vulnerability to policy changes and compresses pricing power over the medium term.
ASKA Pharmaceutical Holdings Co., Ltd. News
4886 FAQ
What was ASKA Pharmaceutical Holdings Co., Ltd.’s price range in the past 12 months?
ASKA Pharmaceutical Holdings Co., Ltd. lowest stock price was ¥1920.00 and its highest was ¥3045.00 in the past 12 months.
What is ASKA Pharmaceutical Holdings Co., Ltd.’s market cap?
ASKA Pharmaceutical Holdings Co., Ltd.’s market cap is ¥60.12B.
When is ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date?
ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date is Aug 04, 2026 which is in 20 days.
How were ASKA Pharmaceutical Holdings Co., Ltd.’s earnings last quarter?
ASKA Pharmaceutical Holdings Co., Ltd. released its earnings results on May 11, 2026. The company reported ¥53.53 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ASKA Pharmaceutical Holdings Co., Ltd. overvalued?
According to Wall Street analysts ASKA Pharmaceutical Holdings Co., Ltd.’s price is currently Overvalued.
Does ASKA Pharmaceutical Holdings Co., Ltd. pay dividends?
ASKA Pharmaceutical Holdings Co., Ltd. pays a Semiannually dividend of ¥32 which represents an annual dividend yield of 2.52%. See more information on ASKA Pharmaceutical Holdings Co., Ltd. dividends here
What is ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate?
ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ASKA Pharmaceutical Holdings Co., Ltd. have?
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding.
What happened to ASKA Pharmaceutical Holdings Co., Ltd.’s price movement after its last earnings report?
ASKA Pharmaceutical Holdings Co., Ltd. reported an EPS of ¥53.53 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.057%.
Which hedge fund is a major shareholder of ASKA Pharmaceutical Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the research, development, production, and commercialization of medications, with a specific focus on endocrinology, obstetrics and gynecology, and urology. Within its animal health segment, ASKA manufactures, sells, imports, and exports a broad spectrum of veterinary products, such as medicines, medical equipment, animal feed and supplements, laboratory reagents, agricultural chemicals, industrial chemicals, hygiene products, and food items along with their raw materials. Beyond these activities, the company also performs clinical and biological testing and offers medical devices. Founded in 1920, ASKA Pharmaceutical Holdings Co.,Ltd. is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---